Top Markets
Coin of the day
TaiwanJ Pharmaceuticals Co., Ltd. TaiwanJ Pharmaceuticals Co., Ltd.

TaiwanJ Pharmaceuticals Co., Ltd.

6549
Clasificación en acciones #30195
TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm... TaiwanJ Pharmaceuticals Co., Ltd. operates as a specialized biotech firm dedicated to the research, development, and commercialization of small molecule therapeutics. Initially, its focus within Taiwan has been on tackling chronic organ inflammation stemming from metabolic, autoimmune, or infectious causes. The company's growing pipeline also features specific compounds like JKB-122 and JKB-121, alongside a collection of innovative chemical entities. These new drugs are being developed to address persistent liver conditions and allergic respiratory ailments, such as asthma. TaiwanJ's comprehensive product portfolio is engineered to combat a wide array of diseases, encompassing hepatic inflammation and fibrosis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), various autoimmune disorders, asthma, and atopic dermatitis (eczema). Established in 2011, the company's operations are headquartered in Zhubei, Taiwan.
Precio por acción
$0.22227521
Capitalización bursátil
$17.81M
Cambio (1 día)
0.00%
Cambio (1 año)
-14.81%
País
TW
Comercio TaiwanJ Pharmaceuticals Co., Ltd. (6549)

Categoría

Ganancias de TaiwanJ Pharmaceuticals Co., Ltd. (6549)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di TaiwanJ Pharmaceuticals Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de TaiwanJ Pharmaceuticals Co., Ltd. desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$3.01B -
BE